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Summary 9'Tc-galactosylated neoglycoalbumin ("mTc-NGA) is a hepatocyte-specific tracer that, after injec-
tion into the blood stream, delivers radioactivity selectively to the liver. This is based upon chemical
recognition and binding by the hepatic binding protein (HBP), a receptor specific for galactosylated glyco-
proteins. Liver tissue samples were obtained intraoperatively from patients undergoing surgery for various
cancers. The concentration of specific HBP receptors in the liver (normal liver, hepatoma, liver metastasis) was
calculated from the in vitro binding of 99mTc-NGA. One week after surgery, the in vivo HBP density was also
measured in some of these patients after injection of 3.5 mg (50 nmol per patient) "mTc-NGA (150-200 MBq)
for simulation of 9'Tc-NGA kinetics. Comparison of in vitro and in vivo HBP concentration in the liver
showed values in the same concentration range. In patients with hepatoma or liver metastasis a significantly
(P<0.01) decreased global HBP density was found in vivo compared to controls. The values obtained for in
vivo HBP concentration in the liver amounted to 0.38 ± 0.05 gmol 1-' liver for patients with hepatoma, to
0.4 ±0.1 gAmol 1- in patients with liver metastasis and to 94 ±0.05timol 1- liver in cancer patients without
liver malignancy. In vitro investigation of HBP density revealed the malignant liver tissue to have a
significantly (P<0.0001) decreased or almost (completely) absent HBP receptor density compared to the
normal tissue apart from the cancer area. It is concluded that determination of HBP density in vivo via a
specific tracer is a new, simple and reliable approach for the determination of remaining hepatic function in
patients with primary or secondary liver cancer.
Methods for the determination of functional liver mass in
patients with liver disease are still being improved. In con-
trast to creatinine clearance as a parameter of kidney func-
tion, the measurement of a single liver function parameter
does not reflect overall hepatic capacity due to the multitude
of metabolic tasks of the liver including synthesis, uptake,
degradation and secretion of bile. Although a number of
quantitative tests of liver function, i.e. elimination of bromo-
sulphophtalein (Haecki et al., 1976), antipyrine (Andreasen et
al., 1974) or aminopyrine (Bircher et al., 1976), exist, they are
usually time consuming, difficult to apply and may have
adverse effects and are therefore not extensively used.
Recently, Stadalnik and co-workers (Stadalnik et al., 1985;
Vera et al., 1985a) introduced a model for in vivo binding
and simulation of a hepatocyte specific tracer, 99mTc-neo-
glycoalbumin C9mTc-NGA), to human hepatic binding pro-
tein (HBP; Stockert & Morell, 1983) in patients with liver
disease in order to evaluate hepatic function from global
HBP receptor density and hepatic blood flow. In these
studies NGA was seen to be hepatocyte-specific and its rate
of accumulation was dependent on the amount of ligand
injected and its affinity to the receptor (Vera et al., 1985b).
Direct evidence for reduction of HBP concentration as a
consequence of hepatocellular pathology was obtained in
studies with chemical carcinogens (Stockert & Becker, 1980),
and positive correlation of reduced in vitro HBP binding
activity and increased circulating inhibitors resulted from a
study of galactosamine-induced liver disease (Sawamura et
al., 1981). Based on these observations we addressed the
question of whether the in vivo HBP density measured by
9'Tc-NGA scintigraphy would be changed in patients with
primary or secondary liver cancer. This study investigated the
in vivo binding of 99mTc-NGA to HBP in patients with nor-
mal livers, hepatomas and liver metastasis. Furthermore, in
order to validate the method described, the in vivo HBP
concentration was compared to the concentration of HBP
measured in vitro at hepatic membranes. This was assessed in
liver tissue samples (normal liver, hepatoma, liver metastasis)
obtained intraoperatively from the same patient one week
before 99mTc-NGA scintigraphy was performed.
Materials and methods
Radiopharmaceutical synthesis and labelling
The organic precursor for the 9"Tc-ligand was synthesised
according to Krohn et al. (1981). Briefly, D(+)-galactose was
acetylated with acetic anhydride to galactose-penta-acetate
which was brominated in C, to give aceto-bromo-galactose.
Aceto-bromo-galactose was reacted with thiourea to give
tetra-acetyl-galactosyl-thiopseudourea which, by reaction
with chloro-aceton-nitrile, formed cyanomethyl-1,3,4,6-tetra-
O-acetyl-p-D-galactopyranoside (A). This intermediate was
purified by recrystallisation and analysed by 'H-NMR.
A solution of 0.1 mol 1' A and 0.01 mol I -' CH3ONa in
absolute methanol was kept at room temperature for 48
hours and then stored as stock solution at - 15C (up to 3
months). It contained on average 0.055 mol I' 2-imino-2-
methoxyethyl-l-thio-p-D-galactopyranoside (B, coupling re-
agent). A measured aliquot of this stock solution (125 pl;
0.055 mol 1-) was evaporated to dryness, redissolved in fresh
0.2 mol 1` borate buffer, pH 8.6, a precise amount of human
serum albumin (HSA; 17 pLI, 20% HSA = 3.4 mg = 50 nmol;
Immuno AG, Vienna, Austria) was added and incubated
over night at room temperature to produce the NGA-ligand.
This was routinely isolated by repetitive ultrafiltration
through a membrane with 20 kDa exclusion limit separating
unbound coupling agent into the filtrate. The number of
galactose residues per HSA-molecule was synthetically con-
trolled by the molar ratio of coupling agent/HSA. According
to a relation set up by Vera et al. (1984), a molar ratio of
coupling agent/HSA = 138 was employed, resulting in about
21 galactose residues per HSA molecule. For each patient,
3.5 mg NGA (50 nmol 3 ml-' per patient) was labelled with
9'Tc in 0.15 mol I' NaCl at pH 2.5 by adding the desired
activity of 99"TcO4 (patient dose 150-200 MBq) and
reducing it with 32 jig Sn2+ generated in situ from a tin
anode and platinum cathode, by applying a d.c. current of
5 mA for 11.4 s in 1 ml labelling volume. After stirring for
30 min, the product was neutralised and finally filtered
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through a sterile 0.2 jim membrane. Radiochemical purity
was routinely monitored by cellulose-acetate electrophoresis
in 0.1 mol 1' barbitone buffer, pH 8.6, run at 300 V for
20min. This system offered the advantage of determining
both free TcO4- and reduced hydrolysed Tc (TcO2 x H20) in
single analysis. Radiochemical purity was typically >97%,
i.e. the 99mTc-NGA peak contained >97% of total "mTc on
the electrophoresis strip. The labelling yield after filtration
through low protein adsorption membranes amounted to
about 95%, in vitro stability at room temperature extended
through more than 10 hours.
Liver membrane preparation
Normal hepatic tissue samples were obtained intraoperatively
from a total of 25 patients aged 44-81 years undergoing
surgery for various cancers of the abdominal tract. In some
patients with liver metastasis (n = 8) or hepatoma (n = 5)
samples from the malignant area were obtained as well.
Histological diagnosis was assessed by haematoxylin and
eosin staining. The tissue removed and designated for the
receptor study was transported immediately to the laboratory
at 4°C.
After calculation of the liver volume (approximately 1 ml),
the tissue was cut into pieces which were suspended in
15-20 ml 50 mmol I` Tris-HCl buffer, pH 7.5, and homo-
genised by means of ultraturrax (Typ 18/10, IKA-Labortech-
nik, Staufen, FRG) and ultrasound (Heat Systems Ultra-
sonic, sonicator W 220F, New York, USA). In order to
study in vitro binding and to calculate the HBP density
for the whole liver this homogenate was directly used for
the binding assays. The homogenate was taken up in assay
buffer containing 50 mmol -' Tris-HCI, 5 mmol [' MgCI2,
5 mmol 1' CaCI2, 1 mol 1' NaCI, pH 7.5, 4°C, and measur-
ed for its protein content by the assay kit provided by
BIO-RAD (Commassie Blue G-250, Richmond, CA, USA).
The protein content in g I` liver was then calculated and
amounted to approximately 100 g -'.
In separate experiments hepatic plasma membranes were
isolated by the method described previously (Neville, 1968;
Virgolini et al., 1989a). The membranes floating on the top of
the 42.1% sucrose were removed and taken up in the same
assay buffer (pH 7.5, 4°C) at a protein concentration of
about 200jig 100 ILl-.
Binding assays
In preliminary studies we used the assay conditions recently
applied also by Vera et al. (1985b) in order to evaluate
99mTc-NGA binding to rabbit HBP. Due to the small and
varying size of liver tissue samples available we finally
reduced the total assay volume from 500 to 200Il (in trip-
licate). Receptor-ligand interaction was studied previously
(Virgolini et al., 1989a). For calculation of the number of
HBP-receptors in normal liver tissue, hepatoma and liver
metastasis, saturation experiments were carried out. There-
fore increasing concentrations (0.01-200 nmol 1') of
99mTc-NGA were incubated with the protein suspension
(200-500jig protein 100;1I-') in the absence (determination
of the total binding) and presence (determination of the
nonspecific binding) of 100jimol 1' NGA. The difference of
total and non-specific binding is referred to as the specific
binding. In competition experiments increasing concentra-
tions of unlabelled NGA (0.01-1000 jLmol 1-') were tested to
displace S nmol 1` of 99mTc-NGA.
To ensure equilibrium (Virgolini et al., 1989a,b), the
incubation time was fixed for exactly 60 min for each sample.
The incubation was performed at room temperature (22°C).
Since the non-specific binding amounted to 5% only (blank
limit), in later experiments only the total binding was
assayed.
A vacuum filtration was employed to separate bound from
free ligand (Virgolini et al., 1988). The dried filters
(Whatman GF/C filter, Maidstone, UK) were taken up in
scintillation fluid (Pico-Fluor TM30, Packard, Downers
Grove, USA) and counted for 1 minute in a liquid scintilla-
tion counter (LKB Wallace, 1215 Rackbeta, Turku, Finland)
at an efficiency of 45%. The inter-assay coefficient of varia-
tion (c.v.) was 6.1 ± 1.1% and the intra-assay c.v.
4.4 ± 0.9%.
Gamma-camera imaging
Kinetic study In all patients the in vivo binding of 'Tc-
NGA to HBP was estimated. The patients were placed in
supine position under a gamma camera (Searle Radio-
graphics Inc., Netherlands) connected to a data processor
(PDP 11/34, Digital Equipment Int. Ltd, Galway, Ireland).
The gamma-camera was equipped with a low energy colli-
mator (140 Kev; Searle). Computer acquisition of gamma
camera data was performed at a rate of two frames per
minute and a matrix of 64 x 64. Time-activity curves were
recorded over precordium and the liver. The total acquisition
time was 30 minutes.
The exact dose of 9'Tc-NGA given to a patient was
calculated from the dose in the syringe before injection and
immediately thereafter and amounted to 4-5 mCi per 3.5 mg
NGA (50 nmol). The exact volume was calculated from the
syringe weight before injection and thereafter. Two minutes
after injection of 99Tc-NGA blood was drawn and transfer-
red into a preweighed plastic tube. The blood concentration
of 99'Tc-NGA was calculated using the activity/gram of this
blood sample and a diluted standard of the labelled product
(1:5,000).
Morphological study Liver morphology was studied by
SPECT scintigraphy performed right after dynamic acquisi-
tion with a double-headed gamma-camera equipped with a
low energy collimator (ROTA-camera, Siemens, FRG).
Using a matrix of 128 x 128, 60 pictures were obtained
within a total exposure time of 5 minutes (angle 300, one turn
lOs).
Analysis
In vitro experiments All data were corrected for the half-life
of "mTc. Calculation of the binding data in terms of Scat-
chard analysis was performed by a computer program (kind-
ly provided by K. Neumann, Ing., Bender & Co., Vienna,
Austria) which searched systematically for the highest level of
correlation unto the model of two straight lines in the given
interval testing against the alternative of a single straight line
approximation (Neumann, 1988).
This program is based on classical least squares method-
ology for the lines fit. The program uses a straightforward
partitioning of regression sums of squares followed by a
standard regression F test.
The corresponding test has been shown within a Monte
Carlo simulation to be rather reliable and on the conservative
side. The purpose of the Monte Carlo simulation was to
show that the implicit multiple decision problem does not
seriously affect the significance levels.
Values are presented as the mean ± standard deviation.
In vivo experiments The in vivo HBP concentration and
hepatic blood flow (Q) were calculated from the time-
activity curves. The kinetic model was developed (and later
published) by D.R. Vera and co-workers (Dept of Nuclear
Medicine, University of California, Sacramento, USA; Vera
et al., 1986). It consists of the haemodynamic subsystem
which delivers the ligand to the target organ, and of the
receptor-binding subsystem in which the formation of the
receptor-ligand complex within the target organ take place.
Following this model, system state equations can be obtained
of the kinetic system which are mathematically represented as
a system of first order non-linear differential equations.
The program runs on a MicrovaxII computer and pro-
duces both the graphical representation of the experimental
and the fitted curves and additional numerical output of the
system parameters, the most important of which are the
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rate constant Kb for the reaction of the ligand with the
receptor in the liver. Furthermore, the program gives esti-
mates on the goodness of fit and of the errors for the various
parameters.
At present we are using two observations: (a) the time
course of radioactivity in the extrahepatic blood which can
be obtained by a region of interest over the precordial area;
(b) the time course of radioactivity in the area of the liver,
which is the sum of two components, the radioactivity of the
free ligand and the radioactivity of the ligand-receptor com-
plex.
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In vitro binding studies
In vitro binding experiments with normal liver parenchyma
revealed high specific binding of 99mTc-NGA to HBP
amounting to 91 ± 7% in the presence of 5 nmol 1-' of 99'Tc-
NGA (Figure 1). The corresponding IC50 (i.e. concentration
causing half maximal inhibition) value was 10-7 mol 1-'.
However, in tissue samples obtained from a malignant area
no relevant in vitro binding activity was observed (<40%) in
the high affinity ligand range. In normal liver tissue the NGA
binding capacity (Bmax) amounted to 6.8 ± 0.9 pmol mg'
total liver protein, being equivalent to 1.13 ± 0.05 tLmol 1'
liver (Table I). In tissue samples derived from hepatomas
(Table II) or liver metastasis (Table III) the NGA binding
capacity was significantly (P<0.0001) lower and amounted
to 0.3 ± 0.05 pmol mg-' total liver protein in hepatoma and
to 0.07 ± 0.05 pmol mg-' total liver protein in liver meta-
0.1 1 10
NGA (umol 1-')
Figure 1 Displacement of "9mTc-NGA binding to normal human
liver (n = 10), hepatoma (n = 5) and liver metastasis (n = 7).
5nmol 1 of b9mTc-NGA (total binding) were incubated with
increasing concentrations of unlabelled NGA (non-specific bin-
ding) and the liver homogenate (200-500 jg 100 il-') in the
presence of 50 mmol 1' Tris-HCI, pH 7.8, 5 mmol 1-' MgCl2,
5mmoll-' CaC12 and I moll' NaCI for 60min at room
temperature (22°C). In the presence of 100-1,000timoll-'
specific binding (the difference of total and non-specific binding)
amounted to 91±7% in normal liver parenchyma and to <40%
in malignant tissue.
stasis. The affinity constant (Kb) amounted to 1.21 ± 0.34
nmol I' in normal liver tissue, to 60.7 ± 11.8 nmol I' in
hepatoma (P<0.001) and to 102 ± 35.4 nmol 1-' in liver
metastasis (P<0.0001).
Table I HBP concentration in patients without liver malignancy
In vitro In vivo
Age (pmolmg-' Kb HBP HBP
Patient (years) Diagnosis protein) (nmolI-') (p.mol I-') (jumolt-')
1 71 Ca of rectum 5.9 1.2 0.976 0.69
2 69 Ca of stomach 6.3 1.2 1.223 0.92
3 72 Ca of rectum 8.0 1.2 1.423 1.00
4 45 Ca of stomach 7.3 0.9 1.095 0.66
5 67 Ca of stomach 6.2 1.0 0.999 1.03
6 75 Ca of esophagus 8.0 0.9 1.120 0.96
7 76 Ca of colon 5.8 1.5 1.150 0.92
8 65 Ca of colon 6.1 0.9 1.000 1.20
9 49 Ca of colon 7.9 1.3 1.320 0.95
10 57 Ca of stomach 6.5 2.0 0.980 1.05
Mean 6.8 1.21 1.13 0.94
±s.d. 0.9 0.34 0.05 0.05
Bmax, binding capacity; Kb, dissociation constant.
Table II HBP concentration in patients with hepatoma
In vitro In vivo
B..
Age (pmolmg-' Kb HBP HBP
Patient (years) protein) (nmol1') (gmol1-') (pmol 1')
1 51 H 0.5 90.2 0.065 0.38
N 6.4 1.4 0.832
2 53 H 0.3 30.2 0.134 0.37
N 7.3 0.90 1.252
3 44 H 0.2 35.4 0.028 0.29
N 5.9 0.70 0.950
4 67 H 0.3 75.3 0.212 0.40
N 6.1 0.85 0.89
5 62 H 0.2 72.4 0.12 0.45
N 5.8 1.10 0.90
Mean ± H 0.3±0.05 60.7± 11.8 0.11±0.07 0.38±0.06
s.d. N 6.3±0.6 0.99±0.27 0.96±0.17
Bma,x binding capacity; Kb, dissociation constant; H, hepatocellular cancer; N, normal
liver tissue.
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Table III HBP concentration in patients with liver metastasis
In vitro In vivo
Bmax
Age (pmol mg-' Kb HBP HBP
Patient (years) protein) (nmol1V') (pmolh') (pmol 1')
1 53 N 5.9 1.4 0.944 0.40
M 0.1 70.5 0.015
2 56 N 7.5 0.8 1.012 0.43
M 0.01 117 0.011
3 37 N 7.3 0.8 0.138 0.42
M 0.01 100 0.009
4 73 N 8.4 1.0 1.321 0.51
M 0.1 80.4 0.140
5 65 N 6.5 0.8 1.345 0.55
M 0.1 45.3 0.085
6 81 N 7.4 1.0 0.962 0.23
M not investigated
7 67 N 8.3 1.0 1.494 0.44
M not investigated
8 54 N 5.9 1.3 1.003 0.34
M 0.15 134 0.19
9 67 N 6.4 1.5 0.896 0.29
M 0.01 152 0.011
10 61 N 7.8 0.7 1.262 0.38
M 0.05 121 0.09
Mean±s.d. N 7.14±0.92 1.03±0.28 1.16±0.22 0.4±0.1
M 0.07±0.05 102.5±35.4 0.07±0.07
Bmax' binding capacity; Kb, dissociation constant; H, liver metastasis; N, normal liver
tissue.
In vivo binding (kinetic) studies
In vivo simulation of QQmTc-NGA-kinetics allowed quanti-
fication of 9"Tc-NGA binding to HBP. In patients without
liver malignancy a normal HBP-concentration of 0.94 ± 0.05
.mol 1I liver was found (Table I). However, in patients with
hepatoma or liver metastasis a significantly decreased
(P<0.01) NGA binding capacity was simulated. The in vivo
measured HBP concentration amounted to 0.38 ± 0.06 ftmol
I` liver in patients with hepatoma (Table II) and to
0.4 ± 0.1 ttmol I` in patients with liver metastasis (Table
III).
Liver morphology - SPECTscintigraphy
In vivo injection of 99mTc-NGA (150-200 MBq) to patients at
a rate of 3.5 mg (50 nmol) demonstrated the liver to be the
only site of tracer uptake. No tracer uptake was found by
SPECT scintigraphy in a malignant liver area (Figure 2).
Figure 2 9'Tc-NGA binding to the liver of a patient (L.G., 73
years, breast cancer) with liver metastasis. SPECT imaging
revealed a lack of tracer uptake in the malignant area (arrows).
Discussion
The objective of the present study was the calculation of the
in vitro and in vivo HBP density in the liver of patients with
primary or secondary liver cancer through the binding char-
acteristics of a new tracer, 9'9Tc-NGA. A direct comparison
of HBP concentration estimated in vivo by 'mTc-NGA func-
tional imaging and HBP concentration measured in vitro on
a surgically removed liver biopsy specimen from the same
patient with a normal liver showed good matching of these
two values, arguing for a good estimation of HBP concentra-
tion in vivo. However, the in vivo estimate of HBP concentra-
tion was always about 75% of that measured in vitro. This
finding in different normal livers indicates a slight but con-
stant underestimation of HBP concentration in vivo.
So far, exact quantification of liver function has not been
possible in a reliable and clinically applicable way. Never-
theless, several clinical situations such as the evaluation of
patients for liver transplantation would make quantitative
liver function tests highly desirable. The development of a
99'Tc-labelled ligand of a hepatic receptor protein specific for
galactose-terminated asialoglycoproteins could provide the
basis for a new approach to the old problem of functional
liver cell reserve.
Until now no real definite physiological role has yet been
ascribed to HBP, although its study has provided many
insights into the biology and pathobiology of the liver. HBP
resides at the cell surface of hepatocytes where it recognises
galactose-terminated glycoproteins (Schwartz et al., 1981;
Stockert & Morell, 1983). Detailed examination of the cel-
lular distribution revealed the parenchymal cells to be the
exclusive sites of hepatic uptake (Stockert et al., 1984).
In this study direct binding experiments were performed to
assess the feasibility of measuring 'Tc-NGA (specific) bind-
ing to human hepatic homogenates or plasma membranes.
The high specificity (91 ± 7%) of the chemically synthesised
NGA-ligand binding to normal liver tissue has provided the
basis for studying changes in receptor density in cancer
patients with or without liver metastasis.
It is known that, once bound at the surface by HBP,
glycoproteins are internalised and transported to pre-
lysosomal vesicles where the majority of the ligand-receptor
complex dissociates by a change to an acid pH (Wall et al.,
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brane (cell surface) while the ligand is degraded in the
lysosomal compartment (Haimes et al., 1981). These findings
make any comparison between the measured in vitro HBP
density and in vivo HBP density somewhat difficult. Although
a different in vitro binding behaviour was found between
99mTc-NGA binding to hepatic plasma membranes and to
homogenates (Virgolini et al., 1989a), the total binding
capacity was similarily pronounced between both prepara-
tions. On the other hand the in vivo binding capacities cal-
culated from the time activity curves generated for the liver
and precordium were comparable to the in vitro data
obtained for normal liver tissue. Thus, in vivo measurement
of HBP density using the naturally occurring 'mTc-NGA
ligand was found to be a valid method for determination of
hepatic function in patients with cancer. The extent of
decrease in HBP concentration in patients with liver meta-
stasis or hepatoma does express the non-functioning hepatic
mass since metastasis or hepatoma do show no uptake in vivo
visualised under the gamma-camera (SPECT scintigraphy)
and in vitro no relevant binding activity. In other experiment-
al studies on chemically induced carcinogenesis the HBP
concentration was reduced too (Stockert & Becker, 1980).
The 99'Tc-NGA kinetic analysis and determination of HBP
density is therefore a simple and valid approach for
quantification of liver function in patients with liver meta-
stasis or hepatoma in vivo. The results suggest that in vivo
estimation of HBP concentration in the liver by 99'Tc-NGA
functional imaging might be an applicable method to deter-
mine functional liver cell mass.
In conclusion, 99'Tc-NGA functional liver imaging may
provide a noninvasive means for the selection of medical or
surgical management in patients with cancer.
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